['diabetes mellitus, type 2']
['canagliflozin, 100 mg', 'canagliflozin, 300 mg', 'placebo']

        Inclusion Criteria:

          -  Must have a diagnosis of T2DM for at least 3 months and be on either metformin
             monotherapy at a stable dose of >=1,000 mg per day or on combination therapy of
             metformin >=1,000 mg per day and a DPP-4 inhibitor at stable daily doses for at least
             12 weeks prior to screening with an HbA1c of >=7.0% and <= 9.5% at Screening

          -  Fasting plasma glucose >=120 mg/dL and <=240 mg/dL at the Week -4 visit

          -  Fasting fingerstick glucose >=120 mg/dL and <=240 mg/dL performed at clinical research
             center on Day -14

          -  Must be medically stable on the basis of clinical laboratory tests performed at
             screening

        Exclusion Criteria:

          -  Has a history of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or
             β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  Has claustrophobia or anxiety, related to previous negative experiences with magnetic
             resonance imaging procedures which cannot be managed with an anxiolytic drug

          -  Has a history of brittle or labile glycemic control, with widely varying glucose
             measurements

          -  Has proliferative diabetic retinopathy (based on an eye examination within one year
             prior to Screening), currently receiving or requiring treatment

          -  Has a history of 1 or more severe hypoglycemic episodes within 6 months before
             screening

          -  Has history of hereditary glucose-galactose malabsorption or primary renal glucosuria.
      